menu
    • menu
    [{"orgOrder":0,"company":"Intrinsic Medicine","sponsor":"Phoenix Biotech Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Termination","leadProduct":"2-Fucosyllactose-Synthetic","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Intrinsic Medicine","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp."},{"orgOrder":0,"company":"Intrinsic Medicine","sponsor":"Phoenix Biotech Acquisition Corp.","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2022","type":"Merger","leadProduct":"2-Fucosyllactose-Synthetic","moa":"","graph1":"Gastroenterology","graph2":"Phase II","graph3":"Intrinsic Medicine","amount2":0.14000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gastroenterology","amount2New":0.14000000000000001,"dosageForm":"","sponsorNew":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp.","highestDevelopmentStatusID":"8","companyTruncated":"Intrinsic Medicine \/ Phoenix Biotech Acquisition Corp."}]

    Find Clinical Drug Pipeline Developments & Deals for 2-Fucosyllactose-Synthetic

    Menu

    2-Fucosyllactose-Synthetic

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Intrinsic Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Intrinsic Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-Fucosyllactose-Synthetic

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Phoenix Biotech Acquisition Corp.

                            Deal Size : $136.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agre...

                            Details : OM002 is a synthetic biology-produced human milk oligosaccharide (HMO) 2’-fucosyllactose, or 2’FL. The single most abundant HMO is 2’FL, which constitutes nearly 30% of the total HMO proportion in human milk.

                            Brand Name : OM002

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 06, 2022

                            Lead Product(s) : 2-Fucosyllactose-Synthetic

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Phoenix Biotech Acquisition Corp.

                            Deal Size : $136.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Intrinsic Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed

                            Intrinsic Medicine

                            U.S.A arrow
                            BMWS24
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2-Fucosyllactose-Synthetic

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase II

                            Sponsor : Phoenix Biotech Acquisition Corp.

                            Deal Size : $136.0 million

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Le...

                            Details : Anticipated cash resources will fund a Phase 2b clinical trial of Intrinsic’s lead, HMO-based drug candidate, OM002 (2’-fucosyllactose, or 2’FL), in over 400 patients with the constipation dominant form of irritable bowel syndrome (IBS-C).

                            Brand Name : OM002

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 31, 2022

                            Lead Product(s) : 2-Fucosyllactose-Synthetic

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase II

                            Sponsor : Phoenix Biotech Acquisition Corp.

                            Deal Size : $136.0 million

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth